DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the third quarter ended September 30, 2016.
Gross business wins in the third quarter were $572 million and cancellations in the quarter were $62 million, resulting in net business wins of $510 million, a net book to bill of 1.21.
In the third quarter net revenue grew 6.4% year on year to $420.2 million from $394.7 million in the same quarter last year.
Income from operations, before non-recurring charges in the quarter, increased by 13.7% to $81.2 million or 19.3% of revenue, compared to $71.4 million or 18.1% for the same quarter last year.
